Jornal do Fígado

Abstrato

Referral of Intermediate and High-Risk Non-Alcoholic Fatty Liver Disease Patients to Hepatology Based on Noninvasive Tests

Sarina Ailawadi, Winston Dunn*

Metabolic-Associated Fatty Liver Disease (MAFLD) is the most common liver disease that affects a quarter of the global population. The disease naming was changed from Nonalcoholic Fatty Liver Disease (NAFLD) to MAFLD because it positively identifies the association with etiology. The disease spectrum includes patients with and without steatohepatitis (AKA Nonalcoholic Steatohepatitis or NASH), as well as with and without significant fibrosis (i.e. stage 2, F2). The prevalence of MAFLD is projected to increase in the coming years due to the increasing prevalence of obesity, diabesity, and metabolic syndrome.